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910(HMG-CoA) reductase inhib-
itors (statins) results in a marked
reduction in atherothrombotic
risk, accompanied by substantial
reductions in circulating markers
of inﬂammation. However, the
effect of statins on atherosclerotic
plaque inﬂammation is less well
established.
Positron emission tomography-
computed tomographic imaging
(PET/CT) with 2-18F-ﬂuoro-
2-deoxy-D-glucose (FDG) has
been explored for measuring arte-
rial inﬂammation. FDG accumu-
lates in human atherosclerotic
arteries in proportion to macro-phage concentration and correlates with gene expression
of macrophage-speciﬁc markers (3–7). FDG uptake re-
ﬂects tissue glycolysis, and it has been shown that activated
macrophages, especially those stimulation through classical/
innate activation pathways (8), have a markedly elevated
glycolytic rate (9,10), and thus avidly accumulate FDG (11).
Arterial FDG uptake correlates with the burden of
cardiovascular risk factors (12–15), is elevated after recent
atherothrombotic events (3,16), and may predict future
atherothrombotic risk (17,18). In addition, studies have
shown that the vascular FDG PET signal is reproducible
(19), allowing serial noninvasive evaluation of plaque
inﬂammation for testing of therapies designed to lower it.
Among such therapies, statins are attractive, given their
well-described effects on cardiovascular events. Tahara
et al. (20) observed, in a single-center open-label study,
a reduction in vascular FDG uptake in patients treated
with low-dose simvastatin at 12 weeks, compared with
patients given dietary advice only. However several
important questions remain unanswered by that study: 1)
whether the observed statin effect on the arterial PET
measurement would be observed under conditions of
a double-blind, multicenter trial; 2) whether a dose
response effect exists between statin therapy and vascular
inﬂammation; and 3) whether the potential reductions
in vascular inﬂammation can be measured as early as 4
weeks after randomization, given that clinical endpoint
trials have demonstrated reductions in cardiovascular
endpoints are observed as early as 1 month after initiation
of statin therapy (21,22).
Clinical trials have repeatedly demonstrated a greater
reduction in cardiovascular events in patients on high- versus
low-dose statin therapy (22,23). We hypothesized that high-
dose statin therapy would be associated with a greater
reduction in plaque inﬂammation (as measured by FDG
uptake) compared with low-dose statin therapy. Accord-
ingly, this represents the ﬁrst double-blind, multicenter trial
using FDG-PET/CT imaging to evaluate the effects of
a statin on vascular inﬂammation.Methods
This double-blind, randomized, active-comparator study
was conducted between August 2008 and December 2009
at 10 U.S. centers located near 1 of 6 imaging centers in
compliance with the principles of the Declaration of
Helsinki and according to Good Clinical Practice
guidelines. The protocol was reviewed and approved by
each center’s institutional review board. All participants
provided written informed consent prior to any study
procedures.
Study population. We sought to study individuals with
arterial inﬂammation. To identify such individuals, we
employed a 2-step approach: 1) to identify, via primary
screening, individuals at higher risk for atherosclerotic
inﬂammation; and then 2) via secondary screening, conﬁrm
the presence of arterial inﬂammation using PET/CT
imaging.
Accordingly, men and women age 30 to 80 years were
included if they had documentation or history of any 1 of
the following: 1) coronary artery disease; 2) carotid artery
disease; 3) cerebrovascular disease; 4) peripheral arterial
disease deﬁned by an ankle-brachial index 0.5 and 0.9;
5) type 2 diabetes mellitus; or 6) body mass index 30 to
40 kg/m2 (inclusive) and waist circumference >102 cm in
men, and >88 cm in women. Additional inclusion criteria
were low-density lipoprotein (LDL) cholesterol 60 mg/dl
and triglyceride level <350 mg/dl. Patients were either statin
naive or on low dose of a statin, deﬁned as atorvastatin
10 mg, simvastatin 20 mg, rosuvastatin 5 mg, pra-
vastatin 40 mg, or ﬂuvastatin 40 mg. Patients were
excluded if they had a history of: 1) signiﬁcant cardiovascular
event or intervention within 12 weeks of screening; 2) type 1
diabetes; 3) signiﬁcant heart failure (e.g., New York Heart
Association functional class III or IV); 4) active or chronic
hepatobiliary disease; or 5) systemic inﬂammatory condition
or infection.
Study procedures. After initial screening, patients under-
went baseline PET/CT imaging. Those with at least 1 vessel
(either the aorta, right carotid, or left carotid) that had an
average maximum target-to-background ratio (TBR) 1.6
were eligible for randomization (24). Prior statin therapy
was discontinued. Patients were randomized 1:1 to either
1  10 mg Lipitor tablet (Pﬁzer, New York, New York) plus
1  80 mg atorvastatin matching placebo daily or 1  80 mg
Lipitor atorvastatin tablet plus 1  10 mg atorvastatin
matching placebo daily for 12 weeks. PET/CT images were
obtained again 4 and 12 weeks following initiation of study
drug.
FDG-PET/CT AND CONTRAST-ENHANCED CT IMAGING. FDG-
PET/CT imaging of the carotid arteries and ascending
thoracic aorta was done using reproducible, validated
methods (4,19). FDG was administered intravenously (10 mCi)
after an overnight fast and imaging was performed 2 h later
using PET/CT. An attenuation correction scan was
obtained using voltage of 140 kVp. Thereafter, PET
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911imaging was performed covering the neck and chest, with 15
min per bed position. Reconstruction of attenuation-
corrected images was done using OSEM algorithm. All
patients had a blood sugar concentration of <200 mg/dl
at the time of imaging. Patients were provided speciﬁc
instructions to follow a low-carbohydrate diet for 24 h before
the test in order to suppress myocardial FDG uptake.
Contrast-enhanced CT imaging was performed once
(at baseline or at Week 4) to provide additional anatomi-
cal information to ensure that the same locations within
the arterial segments are measured across time. CT para-
meters included tube voltage of 120 kVp, tube current of
w750 mAs, section thickness of 0.75 mm, and pitch of
0.2 to 0.4, following injection of intravenous contrast. The
average radiation exposure associated with each PET/CT
was approximately 6 to 7 mCi, while the approximate ra-
diation exposure associated with the CT angiogram was
approximately 15 mCi.
IMAGE ANALYSIS. Images were blinded to patient identiﬁers
and imaging sequence and were analyzed at a central core lab
(Massachusetts General Hospital) using Leonardo TrueD
software (Siemens, Forchheim, Germany). The initial step
of image analysis entailed delineating the pre-deﬁnedFigure 1 PET/CT Endpoints
Regions of interest are drawn around the artery (in axial orientation) to provide a maximum
along the length of the vessel (every w3 mm along the long axis of the vessel) to provid
maximum SUVs are averaged to provide a whole vessel target-to-background ratio (TBR). Si
the single highest SUV, then constructing a stack of 3 ROI using that “most diseased” R
emission tomography/computed tomography.sections of the target vessels on the attenuation correction
CT images (AC-CT) that are provided as part of the PET/
CT dataset. To do so, the temporally blinded image sets
(baseline, 4-, and 12-week PET/CT data) were inspected
and the locations of interest were delineated by comparing
the AC-CT images to ensure that the same locations are
measured across time. For analysis of the carotid artery,
where identiﬁcation of the carotid bifurcation can be chal-
lenging using the AC-CT data alone, the contrast-enhanced
CT images were used to facilitate the identiﬁcation of
the carotid bifurcation. To do so, the contrast-enhanced CT
and AC-CT images were visually compared and the loca-
tion of the carotid bifurcation was marked on the AC-CT.
Thereafter, arterial FDG uptake was measured within
pre-deﬁned sections of the target vessels, guided by the
AC-CT images (which are provided as automatically co-
registered datasets accompanying the PET scans). For the
aorta, measurements were made every 3 mm, starting 1 cm
above the aortic valve annulus, continuing to the bottom of
the aortic arch. For the right and left carotids, measurements
were made every 3 mm, starting 2 cm below the carotid
artery bifurcation, and continuing superiorly to 2 cm into the
internal carotid artery. Measurements were made in the axialstandardized uptake values (SUV) for each region of interest (ROI). This is repeated
e a stack of ROI that compose the whole vessel. Then, the background corrected
milarly, the most diseased segment (MDS) TBR is produced by identifying the ROI with
OI, combined with its immediate inferior and superior neighbors. PET/CT ¼ positron
Tawakol et al. JACC Vol. 62, No. 10, 2013
Statin Intensification Reduces Inflammation September 3, 2013:909–17
912plane by drawing a region of interest around the artery wall
(Fig. 1). The maximum standardized uptake value (SUV)
was recorded for each region of interest. The SUV was
calculated as a time- and dose-corrected tissue radioactivity
divided by body weight. The TBR was calculated from the
ratio of the SUV of the artery compared to background
venous activity, derived from the superior vena cava (for
correction of aortic values), or the internal jugular veins (for
correction of carotid values). The intraobserver and inter-
observer variability of this approach (intraclass correlation
coefﬁcient [95% conﬁdence interval]) are 0.92 (0.75 to
0.98), and 0.98 (0.94 to 1.00), respectively (25).
Arterial FDG uptake (TBR) was evaluated in the 3 target
arterial locations (right and left carotid and aorta). The artery
with the highest FDG uptake at baseline was identiﬁed as
the index vessel, as previously described (20,24). Thereafter,
index vessel FDG uptake (TBR) was calculated using 2
different approaches. The ﬁrst approach (used to evaluate
the primary endpoint) was to deﬁne the average of the
maximum TBR activity within the most diseased segment
(MDS) of the index vessel (MDS TBR). The MDS, in turn
was deﬁned as the 1.5-cm arterial segment, centered on the
slice of artery demonstrating the highest FDG uptake at
baseline, and calculated as a mean of maximum TBR values
derived from 3 contiguous axial segments. The secondFigure 2 Patient Disposition
18FDG ¼ 2-18F-ﬂuoro-2-deoxy-D-glucose; PET ¼ positron emission tomography; PI ¼ prinapproach was deﬁned as the average of the maximum TBR
activity for all of the axial segments that compose the index
vessel (whole vessel TBR with highest mean of maximum
TBR values at baseline).
Statistical analysis. The predeﬁned primary endpoint was
the relative mean change from baseline at 12 weeks in the
arterial 18FDG-PET signal, assessed as a target to background
ratio within the most diseased segment (MDS) of the index
vessel. The pre-deﬁned secondary endpoint evaluated the
relative change in the whole vessel TBRwithin the index vessel.
Exploratory endpoints included: 1) assessment of treatment
effect of relative change in MDS and whole vessel TBR at 4
weeks; 2) assessment of treatment effects on carotid arteries
and aorta separately, at 4 and 12 weeks; and 3) assessment of
the relationship between lipid parameters and TBR.
The primary objective of the study was to determine
whether 12 weeks of treatment with atorvastatin 80 mg
results in a greater reduction from baseline in the FDG-
PET TBR of the MDS when compared to 10 mg of ator-
vastatin. Relative mean changes from baseline in FDG-PET
MDS TBR at 12 weeks were compared between treatments
using an analysis of covariance model including terms
for treatment and baseline covariate (predeﬁned in the ini-
tial protocol), and prior statin use (predeﬁned prior to un-
blinding). The Week 12 geometric mean fold change fromcipal investigator; TBR ¼ target-to-background ratio.
Figure 3 Change in Arterial Inﬂammation
A rapid reduction in arterial inﬂammation was observed after treatment with
statins. This ﬁgure provides the change in MDS TBR at the 4 and 12 weeks
follow-up imaging timepoints after randomization to 10 (n ¼ 33) or 80 mg (n ¼ 34)
of atorvastatin. At 12 weeks, inﬂammation (TBR) in the MDS of the index vessel
was signiﬁcantly reduced from baseline with atorvastatin 80 mg (% reduction
JACC Vol. 62, No. 10, 2013 Tawakol et al.
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913baseline in the mean of the maximum TBR of the MDS was
estimated for each dose and assessed for statistical signi-
ﬁcance between groups. Within group relative changes
from baseline were also assessed as supportive data; hence
no multiplicity adjustment was performed. Data were log
transformed as pre-speciﬁed in the statistical analysis plan.
Differences between treatments were assessed based on the
observed data values, without adjusting for missing data.
Additional sensitivity analyses were performed using mul-
tiple imputation to attempt to correct for any missing data
(Online Appendix). Week 4 data were similarly analyzed.
Associations were tested using Pearson’s correlation coefﬁ-
cient. Multiplicity adjustments were not applied for
secondary comparisons of interest; as such, nominal p values
are reported for all comparisons. Post hoc treatment group
comparisons of baseline variables were performed using
either a Wilcoxon rank sum test for continuous endpoints or
Fisher’s exact test for binary endpoints.
The sample size of 32 patients per treatment group had
77% power to yield a statistically signiﬁcant difference
(alpha ¼ 0.05, 1-sided) in MDS TBR between treatments
if the true underlying difference between treatments is 0.13
(w7% of expected baseline mean TBR 1.9).[95% conﬁdence interval]: 14.42% [8.7% to 19.8%]; p < 0.001), but not
atorvastatin 10 mg (4.2% [–2.3% to 10.4%]; p > 0.1). Atorvastatin 80 mg resulted
in signiﬁcant additional relative reductions in TBR versus atorvastatin 10 mg
(10.6% [2.2% to 18.3%]; p ¼ 0.01) at Week 12. Reductions from baseline in TBR
were seen as early as 4 weeks after randomization with atorvastatin 10 mg
(6.4% reduction, p < 0.05) and 80 mg (12.5% reduction, p < 0.001).
Abbreviations as in Figure 1.Results
Patient information. A total of 163 patients were screened
and 83 patients were randomized (Fig. 2). Exclusion was
due to TBR <1.6 (n ¼ 16), HbA1c >8% (n ¼ 11), fasting
plasma glucose >200 mg/dl (n ¼ 7), and excluded medi-
cations (n ¼ 5). Twelve patients discontinued early due to
adverse experiences (n ¼ 6), withdrawal of consent (n ¼ 2),
protocol deviation, or other reason (n ¼ 4). Patient demo-
graphics were generally comparable across treatment groups
as shown in Table 1.
Effect of atorvastatin on atherosclerotic plaque activity.
Primary endpoint analysis, evaluating change from baseline
in the TBR within the MDS of the index vessel after
12 weeks demonstrated a statistically signiﬁcant relative
reduction from baseline in the atorvastatin 80 mg group
versus atorvastatin 10 mg groups (Table 2, Fig. 3). At
12 weeks a greater reduction in FDG uptake was observed
in patients randomized to atorvastatin 80 versus 10 mg, with
signiﬁcant additional reduction in FDG uptake within the
MDS (10.6% [2.2% to 18.3%]; p ¼ 0.01) Arterial FDG
uptake measurements made at 4 weeks were generally
consistent with those seen at 12 weeks (Fig. 3). Sensitivity
analyses using multiple imputation showed generally
consistent results, with a reduction from baseline in the
atorvastatin 80 mg group of 8.8% (p < 0.05) (Online
Table 1). The impact of baseline measures on the amount
of MDS reduction was modest (estimated correlation ¼
–0.40, p¼ 0.001); and the impact was more pronounced for
the 80 mg group than the 10 mg group. Consistency of the
effect of statins on arterial FDG uptake was observed whenthe carotid arteries (as average of right and left carotid) were
examined separately from the aorta (Online Table 2).
Relationship between lipids and vascular inﬂammatory
activity. Signiﬁcant, dose-dependent reductions from base-
line were observed for total plasma cholesterol, LDL, and
triglycerides (Fig. 4A, Online Table 3). No statistically sig-
niﬁcant, dose-dependent increases in high-density lipoprotein
cholesterol were observed. While a trend between baseline
LDL cholesterol concentrations and baseline MDS TBR
was observed (r ¼ 0.21, p < 0.1) (Fig. 4B), there was no
signiﬁcant correlation between the changes in LDL
cholesterol and changes in TBR during the study (r ¼ 0.04,
p ¼ 0.74) (Fig. 4C). Furthermore, there were no signiﬁcant
relationships between C-reactive protein (CRP) and MDS
TBR, either at baseline (r ¼ 0.11, p ¼ 0.41), or for change
from baseline (r ¼ 0.05, p ¼ 0.73). Likewise, there were no
signiﬁcant relationships between CRP and LDL choles-
terol, either at baseline (r ¼ 0.15, p ¼ 0.23) or for change
from baseline (r ¼ 0.11, p ¼ 0.40).
Effect of statin intensiﬁcation. A post hoc analysis of
the subset of patients in the 80 mg atorvastatin arm who
were receiving a low-dose statin prior to randomization
(n ¼ 18) showed a signiﬁcant reduction in MDS TBR
at 12 weeks versus baseline (13.4% reduction [5.6% to
20.6%]; p < 0.01).
Table 1 Baseline Characteristics by Treatment Group
10 mg Atorvastatin
(n ¼ 34)
80 mg Atorvastatin
(n ¼ 34)
All Patients
(N ¼ 68)
p Value Comparing
Treatment Groups*
Age, yrs 61.0 (53.0–68.0) 58.5 (53.0–68.0) 60.0 (53.0–68.0) 0.549
Male 26 (76%) 26 (76%) 52 (76%) 1.000
Caucasian 27 (79%) 28 (82%) 55 (81%) 1.000
BMI, kg/m2 31.1 (26.9–32.5) 32.0 (26.7–35.5) 31.4 (26.8–33.5) 0.333
Medical history
Type 2 diabetes mellitus 15 (44%) 10 (29%) 25 (37%) 0.315
Coronary artery disease 13 (38%) 15 (44%) 28 (41%) 0.806
Obesity 21 (62%) 24 (71%) 45 (66%) 0.609
Pre-study statin use 22 (65%) 18 (53%) 40 (59%) 0.46
Total cholesterol, mg/dl 176.5 (161.0–192.0) 178.0 (154.0–203.0) 178.0 (157.5–196.5) 0.807
LDL cholesterol, mg/dl 104.0 (86.0–118.0) 107.5 (85.0–129.0) 106.0 (86.0–126.5) 0.643
HDL cholesterol, mg/dl 49.0 (43.0–60.0) 44.0 (39.0–48.0) 46.0 (41.0–56.5) 0.054
Triglycerides, mg/dl 114.5 (78.0–182.0) 129.0 (87.0–179.0) 118.5 (85.5–180.0) 0.625
TBR of index vessel
Most diseased segment 2.34 (2.01–2.93) 2.48 (2.23–2.81) 2.43 (2.14–2.88) 0.646
Whole vessel 2.21 (2.02–2.49) 2.28 (2.06–2.52) 2.24 (2.03–2.52) 0.292
Arterial calciﬁcation
Carotid, aortic or coronary calciﬁcation present, % 88% 82% 85% 0.529
Coronary artery calcium score 27 (6–232) 35 (7–189) 31 (6–200) 0.772
Values are median (interquartile range) or n (%). *Two-sided p value using Fisher’s exact test for binary data and Wilcoxon rank sum test for continuous data.
BMI ¼ body mass index; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; TBR ¼ target-to-background ratio.
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Several novel ﬁndings were observed in this ﬁrst multicenter
feasibility study evaluating the effects of statins on vascular
inﬂammation determined by FDG-PET. First, we observed
a dose response in the reduction in FDG uptake between the
high- and low-dose statin groups. Second, much of the
observed reduction in plaque activity was apparent as early as
4 weeks after randomization to atorvastatin 10 versus 80 mg.
Taken together, these ﬁndings provide evidence of a rapid
reduction in vascular inﬂammation with statin therapy and
provide new insights regarding the graded reductions in
vascular plaque activity as it relates to increases in statin
doses. The results also conﬁrm the ability of PET imaging as
a tool to detect changes in vascular inﬂammation early in theTable 2 Change From Baseline in Index Vessel TBR
TBR Endpoint
Week 4
80 mg Atorvastatin 10 mg Atorvastatin
80 Versus 10
Atorvastati
% Red From BL
(95% CI)
2-sided p Value
% Red From BL
(95% CI)
2-sided p Value
% Red From 10
(95% CI)
2-sided p Val
MDS 12.5
(6.4 to 18.2)
<0.001
6.4
(0.2 to 12.2)
0.04
6.5
(–2.5 to 14
0.15
Whole vessel 7.6
(2.6 to 12.3)
<0.01
2.0
(–3.1 to 6.8)
0.44
5.6
(–3.2 to 13
0.20
For MDS analysis, at Week 4, n ¼ 33 for 10 mg atorvastatin group, n ¼ 30 for 80 mg atorvastatin group.
vessel analysis, at Week 4, n ¼ 33 for 10 mg atorvastatin group, n ¼ 30 for 80 mg atorvastatin group
% Red ¼ percent reduction; BL ¼ baseline; CI ¼ conﬁdence interval; MDS ¼ most diseased segmentcourse of treatment, something not as well validated with
other noninvasive imaging methods (26).
Comparison of study ﬁndings with clinical endpoint trial
experience with statins. Atorvastatin therapy signiﬁcantly
reduces major cardiovascular events, at both low (10 mg) and
high (80 mg) doses (27–29). In addition, an incremental
beneﬁt for 80 mg over 10 mg atorvastatin on the rate of
cardiovascular events was observed in the TNT (Treating
to New Targets: Time to Occurrence of Major Cardiovas-
cular Events Trial) trial (27,28). Similar to cardiovascular
events, an incremental beneﬁt of statin intensiﬁcation was
observed on plaque inﬂammation measured using FDG-
PET imaging as reported in the current study. These data
support the hypothesis that statin therapy may result inWeek 12
mg
n 80 mg Atorvastatin 10 mg Atorvastatin
80 Versus 10 mg
Atorvastatin
mg
ue
% Red From BL
(95% CI)
2-sided p Value
% Red From BL
(95% CI)
2-sided p Value
% Red From 10 mg
(95% CI)
2-sided p Value
.8)
14.4
(8.7 to 19.8)
<0.001
4.2
(–2.3 to 10.4)
0.20
10.6
(2.2 to 18.3)
0.01
.6)
6.7
(1.8 to 11.3)
0.01
-0.1
(–5.6 to 5.1)
0.98
6.8
(–0.1 to 13.2)
0.05
At Week 12, n ¼ 30 for 10 mg atorvastatin group, n ¼ 32 for 80 mg atorvastatin group. For whole
. At Week 12, n ¼ 30 for 10 mg atorvastatin group, n ¼ 33 for 80 mg atorvastatin group.
; TBR ¼ target-to-background ratio.
Figure 4
Relationship Between Lipids and Vascular
Inﬂammatory Activity
(A) Temporal changes in low-density lipoprotein cholesterol (LDL-C) cholesterol in
the 2 treatment groups. (B) Trend between baseline LDL concentrations and
baseline arterial FDG uptake (MDS TBR). (C) Lack of a correlation between LDL-C
lowering and changes in FDG uptake. Abbreviations as in Figures 1 and 2.
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915a reduction in cardiovascular beneﬁt in part due to a rapid
reduction in arterial inﬂammation.
Comparison with circulating biomarkers. In the current
trial, the treatment effects of atorvastatin on circulating
lipid parameters (LDL cholesterol in particular) were
consistent with previous reports. It is interesting that whilst
the changes in both FDG uptake and circulating LDL
cholesterol were directionally concordant and followeda similar time course, there did not appear to be a signiﬁcant
correlation between the 2 parameters at the individual patient
level. This is not unlike ﬁndings from prior larger studies that
also showed modest correlations between inﬂammatory
biomarkers and LDL. For example, in the PROVE-IT–
TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infec-
tion Therapy–Thrombolysis in Myocardial Infarction 22)
trial, the relationship between achieved LDL cholesterol and
achieved CRP levels was modest to nonexistent for the statins
employed in that study (r¼ 0.04, p¼ 0.07 for pravastatin; r ¼
0.15, p ¼ 0.001 for atorvastatin) (30). Accordingly, it is
possible that statins’ effect on vessel wall inﬂammation may
be, at least in part, independent of changes in LDL choles-
terol (“pleiotropic effects”). However, it is also possible that
the current trial lacked the statistical power to provide
evidence of an effect related to changes in LDL cholesterol.
Comparison with prior PET/CT studies. The magnitude
of the change in FDG uptake after treatment with the low-
dose atorvastatin in this study is similar to that seen in the
open-label study using low-dose evaluating simvastatin
versus diet (20), therefore, there is a consistent reduction
in the PET signal associated with low-dose statins. On
the other hand, dalcetrapib, a cholesteryl ester transfer pro-
tein modulator was not associated with changes in the co-
primary FDG-PET endpoint, index vessel MDS as used
in this study (p ¼ 0.37), though a near-signiﬁcant reduction
in the exploratory measure of carotid MDS TBR, was also
noted (p ¼ 0.07) (24). Dalcetrapib was subsequently found
not to be effective in reducing cardiovascular events. Future
studies should evaluate, using drugs from other therapeutic
classes, whether there is a consistent relationship between
changes in the PET signal and clinical beneﬁt.
It remains unclear whether lowering plaque inﬂammation is
a mechanism by which statin therapy decreases cardiovascular
events or even whether reducing arterial inﬂammation trans-
lates into clinical beneﬁt at all. Future studies wherein imaging
is embedded within clinical endpoint trials will be needed to
evaluate the relationship between plaque inﬂammation and
clinical events. Should a relationship between reductions in
plaque inﬂammation and reductions in clinical cardiovascular
endpoints be proven, then targeting plaque inﬂammationmay
ﬁnd a central role in cardiovascular therapy (31).
In this study, larger treatment effects were observed
within the MDS compared to the whole vessel. This was not
unexpected, since the whole vessel is an admixture of dis-
eased and relatively less diseased sections. Accordingly, the
response to effective therapy is expected to be heterogeneous
within the whole vessel. On the other hand, the MDS
represents the region of greatest inﬂammation, hence theo-
retically represents a location that may be more susceptible to
treatment effect. Nonetheless, in the current study, the other
endpoints were all generally consistent and directionally
concordant with the changes seen in the MDS, attesting to
the robustness of the results themselves. It is likely that for
future studies, the MDS should serve as a key endpoint to
compare randomized treatment groups.
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an active comparator arm, no true placebo control group is
included, due to ethical considerations. Second, while
the current trial showed signiﬁcant effects of statins on the
vessel wall at 4 and 12 weeks, it was not designed to evaluate
if these effects persist over longer durations of treatment.
Further work in longer term trials will be required to address
the question of durability of treatment effects. Third, a
substantial number of subjects were unable to provide
complete data sets for analysis (consistent with prior imaging
trial experiences). Nonetheless, analyses of the data that
included and excluded multiple imputation methods
demonstrated similar results, thus enhancing conﬁdence in
the study results.Conclusions
This ﬁrst multicenter trial evaluating the effects of statins on
vascular inﬂammation imaged by FDG-PET has provided
several important insights, including the observation of
a signiﬁcant dose response in the reduction in FDG uptake
between the high- and low-dose statin groups along with
an observation that reductions in plaque activity are appar-
ent as early as 4 weeks after randomization to statins. These
observations are consistent with the ﬁndings from large-scale
event-driven trials of low-versus high-dose statins. Impor-
tantly, the trial data lend strong support to the potential use
of FDG-PET imaging as a tool for early assessment of
treatment effect in patients already taking statins.Acknowledgments
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APPENDIX
For an expanded methods section and additional tables, please see the
online version of this article.
